These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 29278756)

  • 1. Decentralised manufacturing of cell and gene therapy products: Learning from other healthcare sectors.
    Harrison RP; Ruck S; Rafiq QA; Medcalf N
    Biotechnol Adv; 2018; 36(2):345-357. PubMed ID: 29278756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decentralized manufacturing of cell and gene therapies: Overcoming challenges and identifying opportunities.
    Harrison RP; Ruck S; Medcalf N; Rafiq QA
    Cytotherapy; 2017 Oct; 19(10):1140-1151. PubMed ID: 28797612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Centralised versus decentralised manufacturing and the delivery of healthcare products: A United Kingdom exemplar.
    Harrison RP; Rafiq QA; Medcalf N
    Cytotherapy; 2018 Jun; 20(6):873-890. PubMed ID: 29807726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An industry survey of implementation strategies for clinical supply chain management of cell and gene therapies.
    Myles L; Church TD
    Cytotherapy; 2022 Mar; 24(3):344-355. PubMed ID: 34750073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of COVID-19 on the cell and gene therapies industry: Disruptions, opportunities, and future prospects.
    Qiu T; Wang Y; Liang S; Han R; Toumi M
    Drug Discov Today; 2021 Oct; 26(10):2269-2281. PubMed ID: 33892148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How development and manufacturing will need to be structured--heads of development/manufacturing. May 20-21, 2014 Continuous Manufacturing Symposium.
    Nepveux K; Sherlock JP; Futran M; Thien M; Krumme M
    J Pharm Sci; 2015 Mar; 104(3):850-64. PubMed ID: 25630721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancing cell and gene therapy manufacture through the application of advanced fluorescent optical sensors (Review).
    Harrison RP; Chauhan VM
    Biointerphases; 2017 Dec; 13(1):01A301. PubMed ID: 29246035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Manufacturing models permitting roll out/scale out of clinically led autologous cell therapies: regulatory and scientific challenges for comparability.
    Hourd P; Ginty P; Chandra A; Williams DJ
    Cytotherapy; 2014 Aug; 16(8):1033-47. PubMed ID: 24856894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plus ça change, plus c'est la meme chose: to the internal market and back in the British National Health Service?
    Allen P
    Appl Health Econ Health Policy; 2002; 1(4):171-8. PubMed ID: 14619246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Organisational learning.
    Edmonstone JD
    Leadersh Health Serv (Bradf Engl); 2018 Oct; 31(4):434-440. PubMed ID: 30234455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell, tissue and gene products with marketing authorization in 2018 worldwide.
    Cuende N; Rasko JEJ; Koh MBC; Dominici M; Ikonomou L
    Cytotherapy; 2018 Nov; 20(11):1401-1413. PubMed ID: 30366616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Future supply chains enabled by continuous processing--opportunities and challenges. May 20-21, 2014 Continuous Manufacturing Symposium.
    Srai JS; Badman C; Krumme M; Futran M; Johnston C
    J Pharm Sci; 2015 Mar; 104(3):840-9. PubMed ID: 25631279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inter-organisational communication networks in healthcare: centralised versus decentralised approaches.
    Pirnejad H; Bal R; Stoop AP; Berg M
    Int J Integr Care; 2007 May; 7():e14. PubMed ID: 17627296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transitioning from development to commercial: risk-based guidance for critical materials management in cell therapies.
    Scott M; Clarke D; Lipsitz Y; Brandwein H; Allickson J; Alzebdeh D; Aleksic S; Kraft C; Lhu L; Cornetta K
    Cytotherapy; 2020 Nov; 22(11):669-676. PubMed ID: 32713719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Organisational learning within health care organisations.
    Nikula RE
    Int J Med Inform; 1999 Dec; 56(1-3):61-6. PubMed ID: 10659935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cell and gene therapy: a snapshot of investor perspectives.
    Moody J; Milligan WD; St Onge M; Goonewardene A; Rivers P
    Cytotherapy; 2021 Mar; 23(3):256-260. PubMed ID: 33281066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment tool for establishing local pharmaceutical manufacturing in low- and middle-income countries.
    Zimmermann M; Adamson B; Lam-Hine T; Rennie T; Stergachis A
    Int J Pharm Pract; 2018 Aug; 26(4):364-368. PubMed ID: 29732641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Achieving continuous manufacturing: technologies and approaches for synthesis, workup, and isolation of drug substance. May 20-21, 2014 Continuous Manufacturing Symposium.
    Baxendale IR; Braatz RD; Hodnett BK; Jensen KF; Johnson MD; Sharratt P; Sherlock JP; Florence AJ
    J Pharm Sci; 2015 Mar; 104(3):781-91. PubMed ID: 25470351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decentralised systems - definition and drivers in the current context.
    Sharma AK; Tjandraatmadja G; Cook S; Gardner T
    Water Sci Technol; 2013; 67(9):2091-101. PubMed ID: 23656954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How do I structure logistic processes in preparation for outsourcing of cellular therapy manufacturing?
    Chen LN; Collins-Johnson N; Sapp N; Pickett A; West K; Stroncek DF; Panch SR
    Transfusion; 2019 Aug; 59(8):2506-2518. PubMed ID: 31135995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.